Global Single-Use Bioreactors Market is
anticipated to witness a growth of steady CAGR in the forecast period,
2024-2028. This can be ascribed to the increasing
research and development (R&D) activities, collaborations, and strategic partnerships
along with soaring demand for new vaccines, therapeutics, and rising chronic
and infectious diseases. Also, growing development of
monoclonal antibodies are anticipated to create demand for SUBs used for
manufacturing facilities, thereby, expected to drive segment growth. In
January 2022, HaemaLogiX Ltd (HaemaLogiX) and Lonza entered into an agreement for
manufacturing the next clinical batch (cGMP) of HaemaLogiX’s lead multiple
myeloma drug candidate and KappaMab, which is a monoclonal antibody and binds to a cell surface target which is called
as kappa myeloma antigen (KMA) and found on myeloma cancer cells and not on
normal plasma cells.
Increasing demand for biopharmaceuticals
Biopharmaceuticals play a significant role in driving
the growth of the Global Single-Use Bioreactors Market. Biopharmaceuticals are
drugs and vaccines that are produced using living organisms such as bacteria,
yeast, or mammalian cells. Single-use bioreactors are widely used in the
production of these biopharmaceuticals due to their cost-effectiveness,
efficiency, and flexibility. The increasing demand for biopharmaceuticals is one of
the key drivers of the Single-Use Bioreactors Market. Biopharmaceuticals have
become an important component of modern medicine, as they offer targeted and
personalized treatments for various diseases. The Global Biopharmaceuticals
Market is expected to grow at a significant rate, driven by factors such as an
aging population, increasing prevalence of chronic diseases, and the need for
innovative and targeted therapies. Single-use bioreactors offer several advantages over
traditional stainless-steel bioreactors, such as lower capital and operational
costs, reduced risk of cross-contamination, and greater flexibility. These
advantages make single-use bioreactors an attractive option to produce
biopharmaceuticals, particularly for smaller batches and clinical trials.
The biopharmaceutical industry is
adopting new bioprocessing technologies, such as high-density cell cultures and
continuous manufacturing, which require flexible and efficient bioreactors.
Single-use bioreactors can adapt to changing process requirements, making them
ideal for these new technologies.
Cost-effectiveness and efficiency of single-use
bioreactors
Cost-effectiveness and efficiency are key factors
driving the growth of the Global Single-Use Bioreactors Market. Single-use
bioreactors offer several advantages over traditional stainless-steel
bioreactors in terms of cost and efficiency. One of the primary advantages of single-use
bioreactors is their lower capital cost. Traditional stainless-steel
bioreactors require significant upfront capital investments in infrastructure
and equipment, whereas single-use bioreactors require much less capital
investment. This makes single-use bioreactors an attractive option for small
and medium-sized companies, as well as for research and development purposes
to lower capital costs, single-use
bioreactors offer lower operational costs compared to traditional bioreactors.
The use of single-use components, such as bags, filters, and sensors, reduces
the need for cleaning and sterilization, which can be time-consuming and
costly. This reduces the risk of cross-contamination between batches, ensuring
higher quality and more consistent products. Single-use bioreactors offer greater flexibility, which
can lead to increased efficiency. They can quickly and easily set up, allowing
for faster product turnaround times. Single-use bioreactors are more adaptable
to changes in process requirements, making them ideal for research and
development, as well as for small-scale production.